Generated: 2025-11-25 13:17:18
The integrated clinical-risk system highlights UNKNOWN_TARGET_CLASS, DNA, Epidermal growth factor receptor as the dominant mechanistic failure clusters, driven by aggregate toxicity and cross-portfolio propagation.
Clinical attrition remains concentrated in PHASE2 (3122), PHASE3 (1348), PHASE1 (1128), reflecting global R&D late-stage volatility and dose-limiting toxicity trends.
Regulatory observations indicate significant exposure to FDA 21 CFR–defined deviations: STERILITY_FAILURE (135), CONTAMINATION (21), LABELING_PACKAGING (11), signaling potential manufacturing and QA vulnerabilities.
Short-term biomedical evidence activity (7-day) reveals ongoing discussions across trial:148, tox:49, safety:114, withdraw:2, pointing to increased scrutiny around safety and withdrawal risks.
| Phase | Count |
|---|---|
| PHASE2 | 3122 |
| PHASE3 | 1348 |
| PHASE1 | 1128 |
| PHASE4 | 1027 |
| PHASE1, PHASE2 | 694 |
| NA | 589 |
| PHASE2, PHASE3 | 211 |
| UNKNOWN | 164 |
| EARLY_PHASE1 | 139 |
| Target Class | Freq | Avg Score | Weighted |
|---|---|---|---|
| UNKNOWN_TARGET_CLASS | 519 | 0.49 | 311.55 |
| DNA | 132 | 3.48 | 80.24 |
| Epidermal growth factor receptor | 94 | 1.26 | 56.78 |
| Tubulin | 92 | 1.67 | 55.70 |
| Bacterial penicillin-binding protein | 85 | 0.47 | 51.14 |
| Glucocorticoid receptor | 77 | 1.75 | 46.73 |
| Histamine H1 receptor | 72 | 0.39 | 43.32 |
| D(2) dopamine receptor | 68 | 1.01 | 41.10 |
| GABA-A receptor; anion channel | 67 | 1.24 | 40.57 |
| Bacterial 70S ribosome | 67 | 0.72 | 40.42 |
| Sodium-dependent noradrenaline transporter | 65 | 0.78 | 39.24 |
| Sodium channel alpha subunit | 58 | 1.21 | 35.16 |
| Cyclooxygenase | 57 | 1.20 | 34.56 |
| Beta-2 adrenergic receptor | 57 | 0.55 | 34.37 |
| 5-hydroxytryptamine receptor 2A | 56 | 1.51 | 34.05 |
| Mu-type opioid receptor | 54 | 0.95 | 32.68 |
| Estrogen receptor | 49 | 0.86 | 29.66 |
| Receptor-type tyrosine-protein kinase FLT3 | 45 | 1.82 | 27.55 |
| Muscarinic acetylcholine receptor M3 | 45 | 0.68 | 27.21 |
| Androgen receptor | 43 | 1.11 | 26.13 |
| NON_TARGETED_VIRAL_VACCINE | 43 | 0.25 | 25.88 |
| Vascular endothelial growth factor receptor | 41 | 1.97 | 25.19 |
| Receptor tyrosine-protein kinase erbB-2 | 41 | 1.23 | 24.97 |
| Hepatocyte growth factor receptor | 39 | 0.86 | 23.66 |
| Muscarinic acetylcholine receptor M1 | 37 | 0.72 | 22.41 |
| Mast/stem cell growth factor receptor Kit | 35 | 2.72 | 21.82 |
| Human immunodeficiency virus type 1 reverse transcriptase | 35 | 0.74 | 21.22 |
| Sodium-dependent serotonin transporter | 35 | 0.67 | 21.20 |
| Mitogen-activated protein kinase 14 | 35 | 0.34 | 21.10 |
| Progesterone receptor | 34 | 0.98 | 20.69 |
| Vascular endothelial growth factor receptor 2 | 33 | 1.28 | 20.18 |
| Beta-1 adrenergic receptor | 33 | 0.66 | 20.00 |
| Peroxisome proliferator-activated receptor gamma | 31 | 1.03 | 18.91 |
| Topoisomerase IV | 30 | 0.83 | 18.25 |
| Insulin receptor | 30 | 0.73 | 18.22 |
| Bacterial DNA gyrase | 29 | 0.68 | 17.60 |
| 5-hydroxytryptamine receptor 2C | 27 | 1.49 | 16.65 |
| Programmed cell death protein 1 | 26 | 3.45 | 16.64 |
| Voltage-gated L-type calcium channel | 27 | 0.66 | 16.40 |
| Gonadotropin-releasing hormone receptor | 27 | 0.49 | 16.35 |
| 5-hydroxytryptamine receptor 1A | 26 | 1.17 | 15.95 |
| Phosphodiesterase 4 | 26 | 0.79 | 15.84 |
| Serine/threonine-protein kinase mTOR | 26 | 0.64 | 15.79 |
| PI3-kinase class I | 26 | 0.62 | 15.79 |
| Platelet-derived growth factor receptor | 25 | 2.42 | 15.72 |
| Tyrosine-protein kinase JAK2 | 25 | 1.33 | 15.40 |
| Dihydropteroate synthase | 25 | 0.28 | 15.08 |
| DNA topoisomerase 1 | 24 | 0.87 | 14.66 |
| Lanosterol 14-alpha demethylase | 24 | 0.80 | 14.64 |
| Sodium-dependent dopamine transporter | 23 | 1.53 | 14.26 |
| Category | Count |
|---|---|
| STERILITY_FAILURE | 135 |
| CONTAMINATION | 21 |
| LABELING_PACKAGING | 11 |
| MANUFACTURING_OTHER | 10 |
| POTENCY_STABILITY | 10 |
| GMP_DEVIATION | 7 |
| Keyword | Count |
|---|---|
| trial | 148 |
| tox | 49 |
| safety | 114 |
| withdraw | 2 |
| Drug | Score | Summary | Strategies |
|---|---|---|---|
| CYCLOPHOSPHAMIDE | 78.2731 | DNA-damage / genotoxicity cluster. Mechanism-based risk originates from interactions involving DNA. Clinical risk includes 195 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against DNA."] |
| CISPLATIN | 52.6667 | DNA-damage / genotoxicity cluster. Mechanism-based risk originates from interactions involving DNA. Clinical risk includes 131 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against DNA."] |
| CARBOPLATIN | 49.4659 | DNA-damage / genotoxicity cluster. Mechanism-based risk originates from interactions involving DNA. Clinical risk includes 123 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against DNA."] |
| DOCETAXEL | 43.4644 | Microtubule-associated toxicity cluster. Mechanism-based risk originates from interactions involving Tubulin. Clinical risk includes 108 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Tubulin."] |
| PEMBROLIZUMAB | 43.0643 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Programmed cell death protein 1. Clinical risk includes 107 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Programmed cell death protein 1."] |
| DEXAMETHASONE | 40.4485 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Glucocorticoid receptor. Clinical risk includes 97 historical terminated/withdrawn trials. Regulatory alerts detected in.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Review manufacturing and QA processes to eliminate future recall triggers.", "Reduce off-target risk; consider a more selective variant against Glucocorticoid receptor."] |
| CAPECITABINE | 40.3707 | DNA-damage / genotoxicity cluster. Mechanism-based risk originates from interactions involving Thymidylate synthase, RNA, DNA. Clinical risk includes 99 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Thymidylate synthase, RNA."] |
| LENALIDOMIDE | 31.8615 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving CRL4(CRBN) E3 ubiquitin ligase. Clinical risk includes 79 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against CRL4(CRBN) E3 ubiquitin ligase."] |
| BEVACIZUMAB | 30.4998 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Vascular endothelial growth factor A, long form. Clinical risk includes 73 historical terminated/withdrawn trials. Regul.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Review manufacturing and QA processes to eliminate future recall triggers.", "Reduce off-target risk; consider a more selective variant against Vascular endothelial growth factor A, long form."] |
| NIVOLUMAB | 29.4609 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Programmed cell death protein 1. Clinical risk includes 73 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Programmed cell death protein 1."] |
| RITUXIMAB | 29.0608 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving B-lymphocyte antigen CD20. Clinical risk includes 72 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against B-lymphocyte antigen CD20."] |
| EVEROLIMUS | 22.6592 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Peptidyl-prolyl cis-trans isomerase FKBP1A. Clinical risk includes 56 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Peptidyl-prolyl cis-trans isomerase FKBP1A."] |
| TEMOZOLOMIDE | 20.6587 | DNA-damage / genotoxicity cluster. Mechanism-based risk originates from interactions involving DNA. Clinical risk includes 51 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against DNA."] |
| PACLITAXEL | 20.2586 | Microtubule-associated toxicity cluster. Mechanism-based risk originates from interactions involving Tubulin. Clinical risk includes 50 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Tubulin."] |
| CELECOXIB | 19.8585 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Prostaglandin G/H synthase 2. Clinical risk includes 49 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Prostaglandin G/H synthase 2."] |
| LIDOCAINE | 19.8047 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Sodium channel alpha subunit. Clinical risk includes 48 historical terminated/withdrawn trials. Regulatory alerts detect.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Review manufacturing and QA processes to eliminate future recall triggers.", "Reduce off-target risk; consider a more selective variant against Sodium channel alpha subunit."] |
| ATEZOLIZUMAB | 19.4584 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Programmed cell death 1 ligand 1. Clinical risk includes 48 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Programmed cell death 1 ligand 1."] |
| DASATINIB | 18.6582 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Bcr/Abl fusion protein. Clinical risk includes 46 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Bcr/Abl fusion protein."] |
| BUSULFAN | 17.4579 | DNA-damage / genotoxicity cluster. Mechanism-based risk originates from interactions involving DNA. Clinical risk includes 43 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against DNA."] |
| DURVALUMAB | 17.4579 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Programmed cell death 1 ligand 1. Clinical risk includes 43 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Programmed cell death 1 ligand 1."] |
| BUPIVACAINE | 16.6577 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Sodium channel protein type 4 subunit alpha. Clinical risk includes 41 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Sodium channel protein type 4 subunit alpha."] |
| TRANEXAMIC ACID | 16.6577 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Plasminogen. Clinical risk includes 41 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Plasminogen."] |
| AZACITIDINE | 16.6183 | DNA-damage / genotoxicity cluster. Mechanism-based risk originates from interactions involving DNA (cytosine-5)-methyltransferase 1, RNA, DNA. Clinical risk includes 39 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against DNA (cytosine-5)-methyltransferase 1, RNA."] |
| CETUXIMAB | 16.2576 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Epidermal growth factor receptor. Clinical risk includes 40 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Epidermal growth factor receptor."] |
| OXYTOCIN | 16.2576 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Oxytocin receptor. Clinical risk includes 40 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Oxytocin receptor."] |
| ASPIRIN | 14.6572 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Cyclooxygenase. Clinical risk includes 36 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Cyclooxygenase."] |
| GABAPENTIN | 14.6572 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Voltage-gated calcium channel. Clinical risk includes 36 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Voltage-gated calcium channel."] |
| PREDNISONE | 14.6572 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Glucocorticoid receptor. Clinical risk includes 36 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Glucocorticoid receptor."] |
| PROPOFOL | 14.6572 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving GABA-A receptor; anion channel. Clinical risk includes 36 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against GABA-A receptor; anion channel."] |
| AVELUMAB | 14.2571 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Programmed cell death 1 ligand 1. Clinical risk includes 35 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Programmed cell death 1 ligand 1."] |
| CYTARABINE | 13.9641 | DNA-damage / genotoxicity cluster. Mechanism-based risk originates from interactions involving DNA polymerase (alpha/delta/epsilon), RNA, DNA. Clinical risk includes 33 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against DNA polymerase (alpha/delta/epsilon), RNA."] |
| OXALIPLATIN | 13.8570 | DNA-damage / genotoxicity cluster. Mechanism-based risk originates from interactions involving DNA. Clinical risk includes 34 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against DNA."] |
| GEMCITABINE HYDROCHLORIDE | 13.7105 | DNA-damage / genotoxicity cluster. Mechanism-based risk originates from interactions involving Ribonucleoside-diphosphate reductase RR1, DNA polymerase (alpha/delta/epsilon). Clinical risk includes 33 historical ter.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Ribonucleoside-diphosphate reductase RR1, DNA polymerase (alpha/delta/epsilon)."] |
| VORINOSTAT | 13.4175 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Histone deacetylase 3, Histone deacetylase 2, Histone deacetylase 6. Clinical risk includes 31 historical terminated/wit.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Histone deacetylase 3, Histone deacetylase 2."] |
| AZITHROMYCIN | 13.0568 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Bacterial 70S ribosome. Clinical risk includes 32 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Bacterial 70S ribosome."] |
| PEMETREXED | 12.3637 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Thymidylate synthase, Trifunctional purine biosynthetic protein adenosine-3, Dihydrofolate reductase. Clinical risk incl.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Thymidylate synthase, Trifunctional purine biosynthetic protein adenosine-3."] |
| IPILIMUMAB | 12.2566 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Cytotoxic T-lymphocyte protein 4. Clinical risk includes 30 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Cytotoxic T-lymphocyte protein 4."] |
| SIROLIMUS | 12.2566 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Peptidyl-prolyl cis-trans isomerase FKBP1A. Clinical risk includes 30 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Peptidyl-prolyl cis-trans isomerase FKBP1A."] |
| ZOLEDRONIC ACID | 12.2566 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Farnesyl pyrophosphate synthase. Clinical risk includes 30 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Farnesyl pyrophosphate synthase."] |
| TACROLIMUS | 12.0414 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Peptidyl-prolyl cis-trans isomerase FKBP1A. Clinical risk includes 26 historical terminated/withdrawn trials. Regulatory.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Review manufacturing and QA processes to eliminate future recall triggers.", "Reduce off-target risk; consider a more selective variant against Peptidyl-prolyl cis-trans isomerase FKBP1A."] |
| ARSENIC TRIOXIDE | 11.8565 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Thioredoxin reductase 1, cytoplasmic. Clinical risk includes 29 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Thioredoxin reductase 1, cytoplasmic."] |
| EPOETIN ALFA | 11.8565 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Erythropoietin receptor. Clinical risk includes 29 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Erythropoietin receptor."] |
| METHYLPREDNISOLONE | 11.8027 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Glucocorticoid receptor. Clinical risk includes 28 historical terminated/withdrawn trials. Regulatory alerts detected in.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Review manufacturing and QA processes to eliminate future recall triggers.", "Reduce off-target risk; consider a more selective variant against Glucocorticoid receptor."] |
| ARIPIPRAZOLE | 11.5635 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 1A. Clinical risk includes 27 hist.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A."] |
| DECITABINE | 11.5635 | DNA-damage / genotoxicity cluster. Mechanism-based risk originates from interactions involving DNA (cytosine-5)-methyltransferase 1, DNA, DNA (cytosine-5)-methyltransferase 3A. Clinical risk includes 27 historical t.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against DNA (cytosine-5)-methyltransferase 1, DNA."] |
| PREGABALIN | 11.4564 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Voltage-gated calcium channel. Clinical risk includes 28 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Voltage-gated calcium channel."] |
| SIMVASTATIN | 11.4564 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Clinical risk includes 28 historical terminated/withdrawn trials.. | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against 3-hydroxy-3-methylglutaryl-coenzyme A reductase."] |
| IMATINIB MESYLATE | 11.4170 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Platelet-derived growth factor receptor beta, Bcr/Abl fusion protein, Mast/stem cell growth factor receptor Kit. Clinica.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Platelet-derived growth factor receptor beta, Bcr/Abl fusion protein."] |
| ACETAMINOPHEN | 11.1634 | Mechanism-driven vulnerability. Mechanism-based risk originates from interactions involving Fatty-acid amide hydrolase 1, Transient receptor potential cation channel subfamily V member 1, Cyclooxygenase. Clinical.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Fatty-acid amide hydrolase 1, Transient receptor potential cation channel subfamily V member 1."] |
| CLOFARABINE | 11.1634 | DNA-damage / genotoxicity cluster. Mechanism-based risk originates from interactions involving Ribonucleoside-diphosphate reductase RR1, DNA polymerase (alpha/delta/epsilon), DNA. Clinical risk includes 26 historica.... | ["Reassess clinical trial design; strengthen enrollment & monitoring.", "Reduce off-target risk; consider a more selective variant against Ribonucleoside-diphosphate reductase RR1, DNA polymerase (alpha/delta/epsilon)."] |